Apyx Medical reports Renuvion study shows increased elastin, reduced inflammation at 180 days

• Apyx Medical disclosed results from a prospective clinical study of its Renuvion device, now published in a peer-reviewed journal.
• Results have already been presented via publication, not flagged for a future conference presentation.
• Biopsy findings supported improved skin quality signals, with reduced inflammation and favorable tissue remodeling, without safety signals tied to abnormal healing.
• Participants and physicians reported visible aesthetic improvement, with uniformly high satisfaction and recommendation intent.
• Data add human tissue evidence that could support broader procedural adoption and marketing claims for Renuvion in aesthetic surgery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apyx Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290800PRIMZONEFULLFEED9835506) on September 29, 2026, and is solely responsible for the information contained therein.